Aarti Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
April 29, 2023 at 09:23 am EDT
Share
Aarti Drugs Limited reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported sales was INR 7,424.1 million compared to INR 6,942.7 million a year ago. Revenue was INR 7,432.8 million compared to INR 6,972.3 million a year ago. Net income was INR 560.9 million compared to INR 553.4 million a year ago.
For the full year, sales was INR 27,160.5 million compared to INR 24,886.5 million a year ago. Revenue was INR 27,182.5 million compared to INR 24,999.6 million a year ago. Net income was INR 1,663.1 million compared to INR 2,050.4 million a year ago.
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
AARTI DRUGS LIMITED 
